Publication:
Prognostic role of NYHA class in heart failure patients undergoing primary prevention ICD therapy.

dc.contributor.authorBriongos-Figuero, Sem
dc.contributor.authorEstévez, Alvaro
dc.contributor.authorPérez, M Luisa
dc.contributor.authorMartínez-Ferrer, José B
dc.contributor.authorGarcía, Enrique
dc.contributor.authorViñolas, Xavier
dc.contributor.authorArenal, Ángel
dc.contributor.authorAlzueta, Javier
dc.contributor.authorMuñoz-Aguilera, Roberto
dc.date.accessioned2023-02-08T14:38:16Z
dc.date.available2023-02-08T14:38:16Z
dc.date.issued2019-12-11
dc.description.abstractConcerns about the prognostic value of NYHA functional class (FC) in heart failure (HF) patients carrying a prophylactic implantable cardioverter defibrillator (ICD) are still present. We aimed to compare whether mortality and arrhythmic risk were different, in a cohort of HF patients undergoing ICD-only implant, according to their FC. HF patients with left ventricle ejection fraction (LVEF) ≤35%, undergoing first prophylactic ICD-only implant were collected from a multicentre nationwide registry (2006-2015). Six hundred and twenty-one patients were identified (101 patients in NYHA I; 411 in NYHA II; 109 in NYHA III). After a mean follow-up of 4.4 years (±2.1), 126 patients died (20.3%). All-cause mortality risk was higher in symptomatic patients: 13.9% in NYHA I patients, 18.3% in NYHA II patients (HR: 1.8, 95% CI 1.1-3.2), and 32.9% in NYHA III patients (HR: 3.9, 95% CI 2.1-7.3). Seventy-eight out of all deaths were due to cardiovascular causes (12.6%). Cardiovascular mortality risk was also higher in symptomatic patients: 6.9% in NYHA I patients, 11% in NYHA II patients (HR: 2.2, 95% CI 1.1-4.9), and 23.9% in NYHA III (HR: 5.5, 95% CI 2.4-12.7). One hundred and seventeen patients received a first appropriate ICD therapy (19.4%). Arrhythmia free survival did not differ among study groups [20.8% in NYHA I patients, 18.7% in NYHA II (HR: 1.1, 95% CI 0.6-1.7) and 20.8% in NYHA III patients (HR: 1.3, 95% CI 0.7-2.5)]. NYHA class independently predicted cardiovascular mortality (NYHA III vs. NYHA I: HR, 4.7; 95% CI, 1.7-12.8, P = 0.002; NYHA II vs. NYHA I: HR, 2.1, 95% CI, 1.0-5.6, P = 0.05) but not all-cause death (NYHA III vs. NYHA I: HR: 1.8, 95% CI 0.8-3.9, P = 0.11; NYHA II vs. NYHA I: HR, 1.1, 95% CI 0.6-2.2, P = 0.71;). Atrial fibrillation, chronic kidney disease, and diabetes emerged as predictors of both all-cause death [(HR: 1.8, 95% CI 1.2-2.8, P = 0.005), (HR: 2.2, 95% CI 1.4-3.4, P Mortality in HF patients undergoing prophylactic ICD implantation was higher in symptomatic patients. NYHA functional class along with other comorbidities might be helpful to identify a subgroup of ICD carriers with poorer prognosis and higher risk of cardiovascular death.
dc.identifier.doi10.1002/ehf2.12548
dc.identifier.essn2055-5822
dc.identifier.pmcPMC7083467
dc.identifier.pmid31823514
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083467/pdf
dc.identifier.unpaywallURLhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ehf2.12548
dc.identifier.urihttp://hdl.handle.net/10668/14810
dc.issue.number1
dc.journal.titleESC heart failure
dc.journal.titleabbreviationESC Heart Fail
dc.language.isoen
dc.organizationHospital Universitario Virgen de la Victoria
dc.organizationHospital Universitario Virgen de la Victoria
dc.page.number279-283
dc.pubmedtypeJournal Article
dc.pubmedtypeObservational Study
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subjectImplantable cardioverter defibrillator
dc.subjectNYHA functional class
dc.subjectPrognosis
dc.subject.meshCause of Death
dc.subject.meshDeath, Sudden, Cardiac
dc.subject.meshDefibrillators, Implantable
dc.subject.meshFemale
dc.subject.meshFollow-Up Studies
dc.subject.meshHeart Failure
dc.subject.meshHumans
dc.subject.meshIncidence
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshPrimary Prevention
dc.subject.meshPrognosis
dc.subject.meshRetrospective Studies
dc.subject.meshRisk Factors
dc.subject.meshSpain
dc.subject.meshStroke Volume
dc.titlePrognostic role of NYHA class in heart failure patients undergoing primary prevention ICD therapy.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number7
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC7083467.pdf
Size:
1.28 MB
Format:
Adobe Portable Document Format